Related Experiment Videos
Contemporary recommendations for evaluating and treating hyperlipidemia
Insights
Managing hyperlipidemia involves understanding its biochemistry and causes. Effective treatment, including diet and drugs, aims to lower cholesterol and triglyceride levels, especially for coronary artery disease (CAD) risk.
Area of Science:
- Biochemistry and clinical management of lipid disorders.
Background:
- Hyperlipidemia is a significant risk factor for coronary artery disease (CAD).
- The role of elevated triglycerides as an independent risk factor for CAD requires further investigation.
Purpose of the Study:
- To discuss the biochemistry, etiology, evaluation, and management of hyperlipidemia.
- To review various dietary and drug therapies for hyperlipidemia.
Main Methods:
- Laboratory diagnosis relies on repeated measurement of serum or plasma cholesterol and triglyceride concentrations.
- Therapeutic goals include reducing lipid levels, modifying co-existing risk factors, and individualizing treatment.
- Dietary interventions, such as the American Heart Association's three-phase diet, are emphasized.
Main Results:
- Strong evidence links increased cholesterol to CAD.
- The link between elevated triglycerides and CAD is less certain.
- Various drug therapies (e.g., statins, fibrates) are reviewed for their effects on lipids and lipoproteins.
Conclusions:
- Hyperlipidemia management requires a systematic approach considering patient-specific factors and treatment limitations.
- Dietary therapy alone manages most patients.
- Drug therapy is considered for patients with persistent hyperlipidemia despite dietary efforts, particularly those at high risk for CAD.
Abstract:
The biochemistry, etiology, and evaluation of hyperlipidemia and its management, including dietary and drug therapies, are discussed. Strong evidence supports the role of increased cholesterol concentrations as an independent risk factor for coronary artery disease (CAD); however, evidence that elevated triglyceride concentrations are also an independent risk factor remains questionable. The cornerstone of the laboratory diagnosis of hyperlipidemia involves repeated measurement of serum or plasma cholesterol and triglyceride concentrations. The goals of therapy should be to reduce cholesterol or triglyceride concentrations or both to below the 75th percentile, modify co-existing risk factors, individualize the treatment, and minimize any adverse effects. Specific interventions must be determined on the basis of patient age, gender, etiology of hyperlipidemia, presence of other risk factors, and degree of lipid abnormality. The majority of patients may be managed with dietary therapy alone. The three-phase diet developed by the American Heart Association emphasizes a gradual reduction in cholesterol and fats with the substitution of polyunsaturated for saturated fats. Patients at risk for CAD with sustained elevations in plasma cholesterol concentrations above the 95th percentile or a triglyceride concentration above 500 mg/dL after an adequate dietary trial should be considered for drug therapy. The effects of cholestyramine and colestipol hydrochloride, niacin, dextrothyroxine, clofibrate, neomycin sulfate, probucol, gemfibrozil, and mevinolin and compactin on lipids and lipoproteins are reviewed. Hyperlipidemia should be managed systematically using information about the association between increased lipid concentrations and CAD, patient risk factors, and limitations of both diet and drug therapy.